Patents by Inventor J. Mark Cline

J. Mark Cline has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6207659
    Abstract: The present invention relates to a method of using 17&agr;-dihydroequilenin and metabolic conjugates thereof to prevent and reduce atherogenesis in males and females without causing endometrial proliferation in females and without producing feminizing changes in males. 17&agr;-dihydroequilenin was evaluated for its effects on plasma lipid and lipoprotein, glucose, insulin concentrations, coronary artery vasomotor function, and reproductive organ and mammary gland proliferation in atherosclerotic mammals. 17&agr;-dihydroequilenin was found to prevent endothelium-dependent vasoconstriction in males (p<0.05) and ovariectomized females (p<0.08). 17&agr;-dihydroequilenin treatment increased plasma apolipoprotein A-1 concentrations (p<0.05) and lowered fasting insulin concentrations (p<0.05) without changing fasting plasma glucose concentrations in males. 17&agr;-dihydroequilenin had no other effects on plasma lipid and lipoprotein concentrations in either males or females.
    Type: Grant
    Filed: September 9, 1999
    Date of Patent: March 27, 2001
    Assignees: Wake Forest University, American Home Products Corporation
    Inventors: Scott A. Washburn, Thomas B. Clarkson, Michael R. Adams, Thomas C. Register, J. Koudy Williams, Janice D. Wagner, J. Mark Cline, Steven J. Adelman
  • Patent number: 6147069
    Abstract: The present invention relates to a method of using 17.alpha.-dihydroequilenin and metabolic conjugates thereof to prevent and reduce atherogenesis in males and females without causing endometrial proliferation in females and without producing feminizing changes in males. 17.alpha.-dihydroequilenin was evaluated for its effects on plasma lipid and lipoprotein, glucose, insulin concentrations, coronary artery vasomotor function, and reproductive organ and mammary gland proliferation in atherosclerotic mammals. 17.alpha.-dihydroequilenin was found to prevent endothelium-dependent vasoconstriction in males (p<0.05) and ovariectomized females (p<0.08). 17.alpha.-dihydroequilenin treatment increased plasma apolipoprotein A-1 concentrations (p<0.05) and lowered fasting insulin concentrations (p<0.05) without changing fasting plasma glucose concentrations in males. 17.alpha.-dihydroequilenin had no other effects on plasma lipid and lipoprotein concentrations in either males or females. Also, 17.alpha.
    Type: Grant
    Filed: September 9, 1999
    Date of Patent: November 14, 2000
    Assignees: Wake Forest University, American Home Products Corporation
    Inventors: Scott A. Washburn, Thomas B. Clarkson, Michael R. Adams, Thomas C. Register, J. Koudy Williams, Janice D. Wagner, J. Mark Cline, Steven J. Adelman
  • Patent number: 5994337
    Abstract: The present invention relates to a method of using 17.alpha.-dihydroequilenin and metabolic conjugates thereof to prevent and reduce atherogenesis in males and females without causing endometrial proliferation in females and without producing feminizing changes in males. 17.alpha.-dihydroequilenin was evaluated for its effects on plasma lipid and lipoprotein, glucose, insulin concentrations, coronary artery vasomotor function, and reproductive organ and mammary gland proliferation in atherosclerotic mammals. 17.alpha.-dihydroequilenin was found to prevent endothelium-dependent vasoconstriction in males (p<0.05) and ovariectomized females (p<0.08). 17.alpha.-dihydroequilenin treatment increased plasma apolipoprotein A-l concentrations (p<0.05) and lowered fasting insulin concentrations (p<0.05) without changing fasting plasma glucose concentrations in males. 17.alpha.-dihydroequilenin had no other effects on plasma lipid and lipoprotein concentrations in either males or females. Also, 17.alpha.
    Type: Grant
    Filed: January 12, 1998
    Date of Patent: November 30, 1999
    Assignees: Wake Forest University, American Home Products Corporation
    Inventors: Scott A. Washburn, Thomas B. Clarkson, Michael R. Adams, Thomas C. Register, J. Koudy Williams, Janice D. Wagner, J. Mark Cline, Steven J. Adelman
  • Patent number: 5942539
    Abstract: Methods of using phytoestrogens, in particular, isoflavones in the prevention and treatment of endometriosis and related disease conditions in females. One method comprises administering a therapeutically effective dosage of a phytoestrogen to females with endometriosis, females having symptoms related to endometriosis, or to females at risk of developing or suffering recurrence of endometriosis. In another method, at least one phytoestrogen may be administered singly or in combination with at least one hormonal therapeutic agent such as GnRH analogs, androgens, progestins, estrogens or any combination thereof. The therapeutically effective dosage of the phytoestrogen or the combination therapeutic ranges between about 25 and about 250 mg/day.
    Type: Grant
    Filed: October 3, 1997
    Date of Patent: August 24, 1999
    Assignee: Wake Forest University
    Inventors: Claude L. Hughes, Jr., J. Mark Cline, Thomas B. Clarkson, Daniel B. Whitesides